SCHEMBL3570321

SCHEMBL3570321

CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4[nH]c(C(F)(F)F)cc4c3)csc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 13/20 0.62
CSF1R P07333 11/20 0.62
FGFR1 P11362 11/20 0.62
KDR P35968 10/20 0.62
FLT1 P17948 10/20 0.62
FYN P06241 10/20 0.62
LYN P07948 10/20 0.62
FGFR3 P22607 10/20 0.62
BLK P51451 10/20 0.62
LIMK1 P53667 10/20 0.62
NEK2 P51955 10/20 0.62
AURKB Q96GD4 9/20 0.62
MAP4K4 O95819 9/20 0.62
MAP4K2 Q12851 9/20 0.62
FLT3 P36888 9/20 0.62
STK3 Q13188 9/20 0.62
PLK4 O00444 9/20 0.62
SRC P12931 9/20 0.62
RPS6KB1 P23443 9/20 0.62
CSNK1D P48730 9/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3570319 1.00 LCK (0.62) LCKCSF1RFGFR1KDRFLT1
SCHEMBL1378487 0.88 KDR (0.74) LCKCSF1RFGFR1KDRFLT1
SCHEMBL1378490 0.88 KDR (0.74) LCKCSF1RFGFR1KDRFLT1
SCHEMBL3529932 0.85 KDR (0.67) LCKCSF1RFGFR1KDRFLT1
SCHEMBL3529927 0.85 KDR (0.67) LCKCSF1RFGFR1KDRFLT1
SCHEMBL3528115 0.82 KDR (0.65) LCKCSF1RFGFR1KDRFLT1
SCHEMBL3528112 0.82 KDR (0.65) LCKCSF1RFGFR1KDRFLT1
SCHEMBL3530972 0.82 LCK (0.68) LCKCSF1RFGFR1KDRFLT1
SCHEMBL3530966 0.82 LCK (0.68) LCKCSF1RFGFR1KDRFLT1
SCHEMBL3528735 0.81 LCK (0.71) LCKCSF1RFGFR1KDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK LCK 3/4885CSF1R 1197/4885FGFR1 350/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK LCK 3/4885CSF1R 1197/4885FGFR1 350/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK LCK 3/4885CSF1R 1197/4885FGFR1 350/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK LCK 3/4885CSF1R 1197/4885FGFR1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.